Abstract
Pharmaceuticals are a key input in health care systems. For many diseases, they provide the basis of treatment or even the entire treatment. In OECD countries, pharmaceuticals account on average for 10–15% of total health expenditure1. In developing countries, the share of pharmaceuticals is usually higher (up to 50% and more), partly because there is only a limited range of other, more sophisticated services available.
OECD Health Data, 2005, http://www.oecd.org.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Seiter, A. (2007). Access to Medicines and the Innovation Dilemma — Can Pharmaceutical Multinationals be Good Corporate Citizens?. In: Hanekamp, G., Wütscher, F. (eds) Business Ethics of Innovation. Ethics of Science and Technology Assessment, vol ^31. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72310-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-72310-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72309-7
Online ISBN: 978-3-540-72310-3
eBook Packages: EngineeringEngineering (R0)